Abstract
This review of novel oncology drugs approved by the US Food and Drug Administration examines the use of surrogate end points for overall survival, evaluates the use of patient-reported outcomes in trials supporting approvals, and seeks to determine whether drugs initially approved without evidence of overall survival or patient-reported outcome benefits demonstrate improvements in either measure postapproval.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call